European Commissioner for Health and Animal Welfare Olivér Várhelyi on 5 June 2026 detailed the EU's coordinated response to the Ebola outbreak in the Democratic Republic of Congo and Uganda, following an informal meeting of health ministers via video conference. Várhelyi reiterated that the European Centre for Disease Prevention and Control (ECDC) considers the risk of infection for the general public in the EU to be very low, but stressed the need for vigilance and preparedness.
The outbreak, declared a Public Health Emergency of International Concern by the World Health Organization on 17 May, has prompted a series of EU actions. On 22 May, the Health Security Committee issued an opinion with guidance and recommendations to Member States, including risk communication, travel-related measures such as exit screening, and infection prevention protocols. The Committee does not recommend screening of travellers on arrival into the EU or additional travel measures at EU level, but ministers confirmed the importance of monitoring incoming travellers.
The ECDC published a threat assessment on 21 May with laboratory guidance and case definitions, and has deployed expertise to the Africa CDC headquarters through the EU Health Task Force. The European Reference Laboratory for Public Health in Sweden has been activated to support diagnostics. The EU has allocated €15 million to direct response plans, with additional support through existing programmes, including up to €2 billion through the Team Europe Initiative for health manufacturing capacities in Africa.
Várhelyi noted that no vaccine currently exists for this strain of the virus, but the EU is working with the European Medicines Agency, CEPI, Gavi, and the Pandemic Fund to accelerate research and ensure equitable access to vaccines, treatments, and diagnostics. Ministers confirmed that current measures are sufficient and called for continued coordination.
The response has moderate positive impact on affected regions in Africa through financial and technical support, but minimal direct impact on EU citizens given the low risk. EU health authorities and Member States face moderate administrative burden in maintaining surveillance and coordination. The pharmaceutical sector may see moderate opportunities from accelerated vaccine research, while airlines and travel industry face minor operational adjustments from guidance on traveller monitoring.